CVS Caremark plans to start covering Eli Lilly's weekly weight loss pill, Foundayo, in June and will resume covering the company's weight loss injection, Zepbound, by October, the companies announced. Photo by John Angelillo/UPI | License Photo
May 28 (UPI) -- CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months.
Lilly announced the deal with CVS on Thursday about a year after its insurance plans picked up coverage of Novo Nordisk's Wegovy weight loss drug and dropped coverage of Zepbound.
CVS is expected to start covering Foundayo, which is Lilly's most recently approved weight loss drug, on June 1, while it will resume coverage of Zepbound across its plans by October 1, Lilly said in a press release.
The deal means that CVS Caremark's list of covered drugs that insurers and employers can choose to cover will include more weight loss options from Lilly and Novo Nordisk, offering greater choice to an estimated 25 million to 30 million people in the United States, CNBC reported.
